Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes. Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes. t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and t:slim G4 is a trademark of Tandem Diabetes Care, Inc. Forward-Looking Statement This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to the anticipated rate of growth of the company, the company's ability to develop new innovative products and technology and the anticipated date for the transfer of funds for this drawdown under the company's term loan facility with CRG. The company's actual results may differ materially from those anticipated or projected in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the company's insulin pump products may be negatively impacted by a number of factors, including: lack of market acceptance by physicians and people with diabetes; the potential that newer products that compete with this product, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render this product obsolete or less desirable; and the potential that the pump purchasing process, including insurance verification approval for individual customers, may delay or prevent the sale of the pump. Other risks and uncertainties include the company's inability to manufacture products in commercial quantities at an acceptable cost and in accordance with quality requirements; the company's inability to contract with additional third-party payors for reimbursement of the company's products; uncertainty associated with the development and approval of new products generally; possible future actions of the U.S. Food and Drug Administration or any other regulatory body or governmental authority; and other risks identified in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.